Description
The vaccine contains purified tetanus toxoid, adsorbed onto 3 mg/ml aluminum phosphate. Thimerosal 0.1 mg/ml is used as a preservative. One dose 0.5 ml has a potency at least 40 IU. TT is used as the prevention of neonatal tetanus by immunizing women of childbearing age, and also in the prevention of tetanus.
Indication
Active immunization against tetanus
Composition
Each ml of vaccine contains :
Purified tetanus toxoid 20 Lf.
Aluminum phosphate 3 mg
Thimerosal 0.1 mg
Dosage and Administration
The vaccine should be injected intramuscularly or deep subcutaneously.
A sterile needle and a sterile syringe should be use for each injection.
TT immunization for the prevention of tetanus / neonatal tetanus consist of two primary doses of 0.5 ml
given intramuscularly or deep subcutaneously at least four weeks apart followed by the third dose 6-12 months later.
To maintain the immunity of women against tetanus through the childbearing period, five doses are recommended.
The fourth dose should be given at least one year after the third dose, and the fifth dose should be given at
least one year after the fourth dose. TT immunization can be administered safely during pregnancy even at the first trimester.
Side Effects
Rare and mild. Some temporary tenderness and redness at the site of the injection and occasionally fever. It is safe to be given during pregnancy.
Contraindications
A severe reactions to a previous dose of TT. Persons infected with human immunodeficiency virus (HIV) whether asymptomatic or symptomatic, should be immunized with TT vaccine according to certain standard schedules.
Storage and Expiry
Keep at temperature between 2° - 8°C. DO NOT FREEZE.
Expiry date : 2 years
Presentation
Uniject 0.5 ml
